PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou(Pfizer (United States)), Luc Friboulet(Harvard University), David P. Kodack(Harvard University), Lars D. Engstrom(Pfizer (United States)), Qiuhua Li(Pfizer (United States)), Melissa West(Pfizer (United States)), Ruth W. Tang(Pfizer (United States)), Hui Wang(Pfizer (United States)), Konstantinos Tsaparikos(Pfizer (United States)), Jinwei Wang(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Ryohei Katayama(Japanese Foundation For Cancer Research), Dac M. Dinh(Pfizer (United States)), Hieu Lam(Pfizer (United States)), Justine L. Lam(Pfizer (United States)), Shinji Yamazaki(Pfizer (United States)), Wenyue Hu(Pfizer (United States)), Bhushankumar Patel(Harvard University), Divya Bezwada(Harvard University), Rosa L. Frias(Harvard University), Eugene Lifshits(Harvard University), Sidra Mahmood(Harvard University), Justin F. Gainor(Harvard University), Timothy Affolter(Pfizer (United States)), Patrick B. Lappin(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Nathan Lee(Pfizer (United States)), Shibing Deng(Pfizer (United States)), Rakesh K. Jain(Harvard University), Ted W. Johnson(Pfizer (United States)), Alice T. Shaw(Harvard University), Valeria R. Fantin(Pfizer (United States)), Tod Smeal(Pfizer (United States))

Cancer Cell

July 1, 2015

Cited by 463Open Access

Abstract

No related papers found

Powered by citation graph analysis